Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjogren-Larsson Syndrome and noninfectious anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.

Find a broker to begin trading ALDX now

Company Name Aldeyra Therapeutics
Market/Symbol NASDAQ: ALDX
Recent Price
Market Cap $71.88M
Avg. Daily Vol. (3m) 77,649
Price/Book N/A
Price/Cash Flow N/A
As of May. 26, 2017
*Source: QuoteMedia

Begin trading ALDX

 Find Broker

Recent Company Videos

Aldeyra Therapeutics (Nasdaq: ALDX ): RedChip Global Online CEO Conference (July 16-17, 2014).

Aug. 7, 2014

Exclusive Interview with Dr. Todd Brady Chairman and CEO of Aldeyra Therapeutics (Nasdaq: ALDX), a company focused on capturing and removing free ...

Aldeyra Therapeutics Latest News

Ask the CEO

Want more information? View our latest virtual conference.

Receive ALDX Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market